Non-alcoholic steatohepatitis (NASH) is an aggressive form of non-alcoholic fatty liver disease (NAFLD) that may progress to cirrhosis and hepatocellular carcinoma (HCC), and so far, there are limited FDA-approved therapies for NASH. Animal models of NAFLD/NASH are crucial for preclinical evaluation of efficacy and safety. Given the rapidly growing recognition that NAFLD/NASH is the hepatic manifestation of metabolic syndrome, scientists are paying a lot more attention to the metabolic characteristics of NASH animal models they choose to work with.
GemPharmatech has generated several NASH models for preclinical research, including diet or chemical induced NASH models and genetically engineered mouse models for NASH.
The topics for this webinar are:
Comparison of classic mouse models for NASH
Overview of our NAFLD/NASH models
Application of NASH models for drug development
PDT 8:00 am | CDT 10:00 am | EDT 11:00 am | CEST 17:00 pm, May 30th, 2023